wire - news in brief

« BACK

Health



Results 2151 - 2200 of 2202.
« Previous 1 ... 40 41 42 43 44 ... 45 Next »


Pharmacology - Health - 27.05.2010
Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint
Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint Basel, May 27, 2010 - Novartis announced today that patupilone (EPO906) did not show a significant overall survival advantage in a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy The comparator arm in the trial was Doxil /Caelyx (pegylated liposomal doxorubicin).

Health - Pharmacology - 22.05.2010
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes Study shows around 40% of ranibizumab patients substantially impr

Life Sciences - Health - 11.05.2010
Swiss scientists sequence fire blight genome
Swiss scientists sequence fire blight genome
Wädenswil, 11.05.2010 - Researchers at Agroscope Changins-Wädenswil ACW have published the first complete genome sequence of the fire blight pathogen, Erwinia amylovora.

Health - Life Sciences - 04.05.2010
Mechanism elucidated for a rare disease
Scientists at the Friedrich Miescher Institute for Biomedical Research (FMI, part of the Novartis Research Foundation) have dissected one of the molecular mechanisms underlying Friedreich's ataxia. In doing so, they have shed new light on the pathogenic mechanism of the disease. These findings could lead to the development of new therapeutic approaches for what is, as yet, an incurable condition.

Life Sciences - Health - 26.04.2010
Odors classified by networks of neurons
Odors classified by networks of neurons
Scientists at the Friedrich Miescher Institute for Biomedical Research (FMI, part of the Novartis Research Foundation), are unraveling how odors are processed by the brain. As they report, odors in the olfactory brain are classified into groups represented by discrete activity states of neuronal circuits.

Health - Pharmacology - 23.04.2010
Novartis gains new indication for Diovan for the treatment of children and adolescents with high blood pressure in the EU
Novartis gains new indication for Diovan for the treatment of children and adolescents with high blood pressure in the EU New indication brings the world's number one selling high blood pressure medi

Pharmacology - Health - 22.04.2010
Novartis receives US FDA approval for Zortress® (everolimus) to prevent organ rejection in adult kidney transplant recipients
Novartis receives US FDA approval for Zortress® (everolimus) to prevent organ rejection in adult kidney transplant recipients Zortress offers kidney transplant recipients a new option for preventing

Pharmacology - Health - 13.04.2010
Novartis investigational multiple sclerosis therapy Gilenia®* (FTY720) shown to reduce relapse rates regardless of treatment history
Basel, April 13, 2010 - Data presented at the American Academy of Neurology (AAN) annual meeting add to the accumulating evidence of the positive benefit/risk profile of Gilenia, a potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis (MS).

Pharmacology - Health - 13.04.2010
Novartis investigational multiple sclerosis therapy Gilenia * (FTY720) shown to reduce relapse rates regardless of treatment history
Novartis investigational multiple sclerosis therapy Gilenia * (FTY720) shown to reduce relapse rates regardless of treatment history New extension data show Gilenia effect sustained over two years; also highlights potential benefits of switching from interferon beta-1a Basel, April 13, 2010 - Data presented at the American Academy of Neurology (AAN) annual meeting add to the accumulating evidence of the positive benefit/risk profile of Gilenia, a potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis (MS).

Life Sciences - Health - 09.04.2010
Strengthening stem cell research in Switzerland
When it comes to treating incurable diseases, hopes are high for stem cells because they can develop into a multitude of specialized cells. But despite rapidly accumulating and promising results - stem cells are for instance implicated in the treatment of Type 1 diabetes- the nature, function and differentiation capacity of stem cells are still poorly understood.

Health - Pharmacology - 18.03.2010
Novartis receives approval in the European Union for Menveo , first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
Novartis receives approval in the European Union for Menveo , first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease Meningococcal disease is a major cause of bacterial

Life Sciences - Health - 16.03.2010
The Friedrich Miescher Institute for Biomedical Research turns 40!
The Friedrich Miescher Institute for Biomedical Research turns 40!
March 16 2010 The Friedrich Miescher Institute for Biomedical Research turns 40! Today, the Friedrich Miescher Institute for Biomedical Research, part of the Novartis Research Foundation, is celebrating its 40th birthday.

Health - Life Sciences - 16.03.2010
EPFL becomes world center for tuberculosis study
Tuberculosis still affects thousands of victims worldwide.

Life Sciences - Health - 16.03.2010
The Friedrich Miescher Institute for Biomedical Research turns 40!
Today, the Friedrich Miescher Institute for Biomedical Research, part of the Novartis Research Foundation, is celebrating its 40th birthday.

Event - Health - 09.03.2010
FBM Talents of the year 2010
Premier rang de gauche à droite: Oscar Matzinger, Marie-Denise Schaller, Marie-Claude Hofner, Patrice Guex, Nicolas Salamin.

Health - Pharmacology - 27.01.2010
Ein fataler Kreislauf
Zurich - University of Zurich Eine Studie der Psychiatrischen Universitätsklinik Zürich hat erstmals die Schweizer Drogenpolitik von 1975 bis 2007 untersucht.

Health - Pharmacology - 26.01.2010
Die Ergotherapie von morgen findet am Computer statt
Zurich - University of Zurich Nach Hirnverletzungen müssen Patienten Bewegungen neu einüben. Neuerdings helfen ihnen dabei Computergames.

Astronomy / Space Science - Health - 21.01.2010
  Mit dem Tiger forschen
Zurich - University of Zurich Die Universität Zürich und die Schweizer Luftwaffe haben ein weltweit einzigartiges Forschungsvorhaben in der Weltraummedizin gestartet.

Pharmacology - Health - 20.01.2010
Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression as published in New England Journal of Medicine
Results of the TRANSFORMS and FREEDOMS studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine , providing compreh

Health - Pharmacology - 20.01.2010
Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer
Basel - Novartis Basel, January 20, 2010 - Patients in Japan will benefit from the approval of three new Novartis medicines - Equa® (vildagliptin), marketed as Galvus® in the European Union , for t

Health - 20.01.2010
Prof. Martin Täuber wird neuer Rektor der Universität Bern
Bern - Universität Bern Der Regierungsrat des Kantons Bern hat den Medizinprofessor Martin Täuber zum künftigen Rektor der Universität Bern gewählt.

Health - Pharmacology - 13.01.2010
Mikro-Teile gegen Anämie
Zurich - University of Zurich Für Hämoglobin-Erbkrankheiten gibt es gute Therapien. Weiterhin ist aber ein Teil der Patienten auf regelmässige Transfusionen angewiesen.

Pharmacology - Health - 11.01.2010
Novartis launches schizophrenia treatment Fanapt in the US, offering patients an attractive alternative to existing medications
"Schizophrenia remains one of the most debilitating and difficult to treat mental illnesses.

Economics / Business - Health - 04.01.2010

Pharmacology - Health - 23.12.2009
Novartis to acquire Corthera Inc., gaining worldwide rights to Phase III project relaxin for treatment of acute decompensated heart failure
Basel - Novartis - Novartis will gain exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide, through the acquisition of the privately held US biopharmaceutical company Corthera Inc.

Health - Pharmacology - 21.12.2009
All three Novartis A(H1N1) 2009 influenza vaccines prequalified by World Health Organization (WHO) for use in developing world
Basel - Novartis WHO prequalification facilitates purchasing through UN agencies and thus enhances access for developing world countries to Novartis A(H1N1) 2009 vaccines that meet unified standards of quality and safety.

Health - Pharmacology - 18.12.2009
Novartis meningococcal vaccine Menveo® recommended for approval in the European Union for prevention of disease in adolescents and adults
Basel - Novartis (Meningococcal Group A, C, W-135 and Y-CRM Conjugate Vaccine) has received a Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA).

Life Sciences - Health - 16.12.2009
Was Affenmännchen treu macht
Zurich - University of Zurich Männliche Menschenaffen haben wechselnde Partnerinnen und schenken ihrem Nachwuchs kaum Beachtung.

Health - Life Sciences - 14.12.2009
Wenn verletzte Nerven wieder wachsen
Zurich - University of Zurich Der Hirnforscher Martin Schwab entwickelt ein neues Medikament, um Querschnittgelähmte zu behandeln.

Health - Pedagogy - 10.12.2009
«Das Problem nimmt insgesamt zu»
Zurich - University of Zurich Auch diese Weihnachten werden viele Kinder Computerspiele auf dem Gabentisch finden.

Pharmacology - Health - 09.12.2009
Novartis set to sustain its leading global position in oncology with portfolio targeting various tumors and life-threatening diseases
09.12.2009 / Basel - Novartis Basel, December 9, 2009 - Novartis is set to sustain its leading global position in oncology by expanding the range of indications for several marketed the

Pharmacology - Health - 08.12.2009
Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia
08.12.2009 / Basel - Novartis At 12-month milestone, significantly fewer patients progressed to accelerated or blastic phase on Tasigna 300 mg twice daily than on Glivec 400 mg once dai

Pharmacology - Health - 03.12.2009
Novartis receives approval in the European Union for Onbrez® Breezhaler®, a new once-daily bronchodilator for patients with COPD
03.12.2009 / Basel - Novartis Basel, December 3, 2009 - Novartis announced today that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg

Health - Pharmacology - 02.12.2009
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
02.12.2009 / Basel - Novartis Basel, December 2, 2009 - Novartis announced today that new data, including a late-breaking presentation on Tasigna"(nilotinib) in a form of chronic myeloi

Health - 30.11.2009
How calcium ions control muscle power
30.11.2009 / Bern - SNF The penetration of calcium ions, which cause muscle cells to contract, is visible under a TIRF microscope.

Pharmacology - Health - 25.11.2009
Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
25.11.2009 / Basel - Novartis Ex-US rights acquired for JAK inhibitor INCB18424 in Phase III development as first-in-class treatment for myelofibrosis, a life-threatening blood disorder

Health - Pharmacology - 24.11.2009
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
24.11.2009 / Basel - Novartis Facility designed to supply 150 million doses of pandemic vaccine within 6 months of influenza pandemic declaration; facility ready to respond to a pandemi

Health - Pharmacology - 17.11.2009
Novartis Influenza A(H1N1) 2009 vaccine US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1)
17.11.2009 / Basel - Novartis Interim clinical data from approximately 4,000 individuals suggest that half a dose of the currently US-approved Novartis unadjuvanted Influenza A(H1N1) 20

Health - Pharmacology - 13.11.2009
Novartis receives approval in Switzerland for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine
13.11.2009 / Basel - Novartis Approvals in Germany and Switzerland demonstrate expanded adoption of new cell culture technology - an important milestone in replacing 50 year-old egg-bas

Pharmacology - Health - 12.11.2009
Novartis launches Prevacid®24HR over-the-counter for full 24-hour frequent heartburn treatment
12.11.2009 / Basel - Novartis Prevacid®24HR provides America 's 50 million frequent heartburn sufferers with convenient and easy accessibility to this effective heartburn treatment Bas

Health - Pharmacology - 05.11.2009
Novartis receives regulatory approval in Germany for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine
05.11.2009 / Basel - Novartis Clinical trials in more than 1,850 individuals across all age groups show strong efficacy, that can induce immune responses associated with protection agai

Health - Pharmacology - 29.10.2009
Novartis on track to deliver Influenza A (H1N1) vaccine for the US
29.10.2009 / Basel - Novartis To date, Novartis has shipped more than 7.5 million doses of Influenza A (H1N1) vaccines in multi-dose vials and pre-filled syringes ready to use, a

Health - Pharmacology - 28.10.2009
Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease
28.10.2009 / Basel - Novartis Ilaris is a monoclonal antibody that selectively targets and blocks interleukin-1 beta (IL-1ß), the trigger for inflammation and tissue damage in CAPS pat

Pharmacology - Health - 23.10.2009
Novartis receives approval in the European Union for Exforge HCT®, a new 3-in-1 treatment for high blood pressure
23.10.2009 / Basel - Novartis Basel , October 23, 2009 - The European Commission has granted Novartis marketing authorization for Exforge HCT" a new 3-in-1 treatment for people with high blood pressure.

Health - Pharmacology - 22.10.2009
Novartis delivers strong new product momentum and operational performance in first nine months of 2009
22.10.2009 / Basel - Novartis Net income of USD 6.1 billion down 8% due to negative currency impact, Alcon-related financing costs and USD 189 million of associated companies cha

Health - Pharmacology - 20.10.2009
New Phase II data show ACZ885 gave better pain relief and flare prevention for patients with chronic gout than an injectable corticosteroid
20.10.2009 / Basel - Novartis Basel, October 20, 2009 - New Phase II results show that the novel biological therapy ACZ885 (canakinumab) is significantly more effective than an injectab

Pharmacology - Health - 20.10.2009
Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec® as first-line treatment in chronic myeloid leukemia patients
20.10.2009 / Basel - Novartis Basel, October 20, 2009 - Novartis announced today that Tasigna® (nilotinib) met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Glivec® (imatinib).

Pharmacology - Health - 19.10.2009
Novartis receives Complete Response letter from FDA for QAB149, an investigational bronchodilator for COPD
19.10.2009 / Basel - Novartis Basel, October 19, 2009 - Novartis has received a Complete Response letter from the US Food and Drug Administration (FDA) as part of the US regulatory revi

Health - Pharmacology - 19.10.2009
Leading Dengue and TB scientists discuss new clinical research approaches and models of excellence for clinical research and trials in endemic regions
19.10.2009 / Basel - Novartis NEHCRI is a unique role model for clinical TB and Dengue research in endemic regions, utilizing local input to build capacity and develop health infrastruc

Pharmacology - Health - 12.10.2009
Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM), an FDA-approved oral therapy for schizophrenia
12.10.2009 / Basel - Novartis Basel, October 12, 2009 - Novartis Pharma AG has entered into an agreement for exclusive US and Canadian rights to Fanapt(TM) (iloperidone), a new oral med
« Previous 1 ... 40 41 42 43 44 ... 45 Next »